Locations:
Search IconSearch
July 27, 2017/Cancer

How Do Older Adults Feel About Forgoing Cancer Screenings?

Study looks at doctor-patient communication on screenings

Genetics

Cancer screenings are part of standard medical care, however, recent studies are showing that patients of advanced age or illness often do not benefit from this testing. A team at The Johns Hopkins University School of Medicine recently conducted a study to get a deeper understanding of older adults’ perspectives on screening cessation and communication with clinicians on this topic. Ronan Factora, MD, answers a few questions about study results.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Is this research important?

Discussions about cancer screening occur very frequently in the clinical setting, and knowledge of the kind of language that is most effective can help physicians refine their technique.

What is the key take home message from this study?

There were several take home messages. Patients state that their trust in the physician is the biggest influence on whether or not they agree with the physician’s recommendations to screen or not screen. We also learned that the use of the term “life expectancy” had limited usefulness to the patient. Health status seemed to be a more important factor for patients when making a decision to forgo further cancer screening. Patients preferred to hear statements like “this test is not going to help you live longer” or “this test is not going to be helpful,” rather than statements like “you are not going to live 10 years.”

Should the findings change patient management?

Yes. The perception of the patient in using terms such as “life expectancy” and “health status” should prompt physicians to avoid using terms that are misunderstood or ambiguous. Framing cancer screening discussions in the context of whether or not the screening will allow a patient to live longer appears to be more successful.

What are the study’s strongest points?

The study sampled individuals from a broad range of locations (ambulatory settings, home, primary care, internal medicine and geriatric medicine), and it is likely that patients seen at these locations would have similar perspectives. Individuals interviewed were 75 and older and representative of the general population.

What are the main limitations of the study?

There were limited numbers of individuals involved, many of whom had a trusting relationship with their physicians. It is unclear if there would be similar results in a discussion with physicians that the patients did not know so well. The study also relied on self-reporting for the data, so responses to questions may not reflect how individuals would act in real life.

Advertisement

Though individuals with cognitive impairment were included in this study, many individuals with significant enough cognitive impairment require a surrogate decision maker to help them. It is unclear how surrogate decision makers would react to this discussion.

Go to PubMed Journals for more details and a link to JAMA for the full article.

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad